Adverum Biotechnologies Stock Price

0.25 (1.87%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Adverum Biotechnologies Inc ADVM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.25 1.87% 13.64 14:28:57
Open Price Low Price High Price Close Price Prev Close
13.31 13.1787 13.90 13.39
Bid Price Ask Price Spread News
13.63 13.68 0.05 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,812 507,543 $ 13.61 $ 6,906,315 1,238,578 7.36 - 26.98
Last Trade Time Type Quantity Stock Price Currency
14:28:57 10 $ 13.68 USD

Adverum Biotechnologies Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.33B 97.48M 89.84M $ 250.00k $ - -1.01 -10.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Adverum Biotechnologies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ADVM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week11.4914.7911.3113.391,436,3562.1518.71%
1 Month12.4014.7910.5512.251,003,1841.2410.0%
3 Months11.1214.7910.5512.691,029,6202.5222.66%
6 Months17.3719.35999.8312.741,072,806-3.73-21.47%
1 Year11.1126.987.3614.291,240,8462.5322.77%
3 Years5.9526.982.6210.311,039,5867.69129.24%
5 Years6.3626.982.409.25744,3237.28114.47%

Adverum Biotechnologies Description

Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. The company is committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye, who currently have limited or burdensome treatment options. Its services are focused on advancing three lead gene therapy programs to address unmet needs in wet age-related macular degeneration and in rare diseases alpha-1 antitrypsin deficiency and hereditary angioedema. Its leading programs include ADVM-022, ADVM-043 and ADVM-053.

Your Recent History
Adverum Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.